{"id":"active-comparator-timolol-0-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Bradycardia (systemic absorption)"},{"rate":null,"effect":"Bronchospasm (in susceptible patients)"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":{"chemblId":"CHEMBL1200870","moleculeType":"Small molecule","molecularWeight":"432.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The 0.5% formulation is a topical ophthalmic solution applied directly to the eye.","oneSentence":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:07.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03519386","phase":"PHASE3","title":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-07-26","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":590},{"nctId":"NCT03868124","phase":"PHASE3","title":"Clinical Study Comparing Two Models of a Travoprost Intraocular Implant","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-09-17","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":560},{"nctId":"NCT02250651","phase":"PHASE3","title":"Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-12-15","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":528},{"nctId":"NCT02247804","phase":"PHASE3","title":"Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-12-15","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":594},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01026831","phase":"PHASE3","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":643},{"nctId":"NCT00449956","phase":"PHASE3","title":"MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-12","conditions":"Glaucoma","enrollment":474},{"nctId":"NCT00108017","phase":"PHASE3","title":"Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":330},{"nctId":"NCT00972426","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2009-10","conditions":"Glaucoma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active Comparator: Timolol 0.5%","genericName":"Active Comparator: Timolol 0.5%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}